Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | IKBKB | O14920 | 3/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL7404680 | 0.97 | KDM4E (0.61) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL7404678 | 0.97 | KDM4E (0.61) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL28343362 | 0.91 | IDO1 (0.64) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL1802393 | 0.88 | KDM4E (0.57) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL29374999 | 0.86 | MAPT (0.63) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL2205716 | 0.86 | IDO1 (0.70) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL550901 | 0.86 | MAPT (0.63) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL8140936 | 0.84 | IRAK4 (0.54) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL9127062 | 0.83 | MAPT (0.59) | KDM4EALDH1A1GAAIKBKBIRAK4 | |
| SCHEMBL5750206 | 0.83 | IDO1 (0.66) | KDM4EALDH1A1GAAIKBKBIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| JP-1149759-A | — | — | None | — | — | JP | disclosed |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2020150446-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150446-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-07-23 | — | — | WO | disclosed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5220048-A | Diels-Alder reactions | CIBA-GEIGY CORPORATION (US) | 1993-06-15 | — | — | US | disclosed |
| JP-H01149759-A | PRODUCTION OF 2,3-DICYANONAPHTHALENE | NIPPON SHOKUBAI KAGAKU KOGYO CO LTD | 1989-06-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | KDM4E 4735/4885ALDH1A1 1816/4885GAA 4868/4885 |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | KDM4E 1766/4885ALDH1A1 1856/4885GAA 1355/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | KDM4E 1766/4885ALDH1A1 1856/4885GAA 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.